The technology has the potential to provide life-saving support for the approximately 20 million ICU patients with respiratory failure annually

RA'ANANA, Israel, Jan. 14, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, is proud to announce the development of a modular configuration for its groundbreaking VORTX blood oxygenation delivery technology. We believe that this innovative approach represents a significant advancement in the field of extracorporeal oxygenation and has the potential to transform critical care practices worldwide.

RA'ANANA, Israel, Jan. 10, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ART100 device. This strategic readiness comes in light of the recent outbreak of human metapneumovirus (hMPV) in China, which has highlighted the growing need for advanced respiratory care technologies globally.

Inspira is already in discussions with leading providers in affected regions to evaluate demand for advance respiratory solutions and deployment of the INSPIRA™ ART100 device, ensuring rapid response capabilities in case of increased demand.

Visitors at Glo-Med Network Inc's booth can explore Inspira's cutting-edge respiratory solutions, with the FDA-cleared INSPIRA™ ART100, showcasing the future of respiratory care

RA'ANANA, Israel, Jan. 7, 2025 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory support technology company, is pleased to announce that the INSPIRA™ ART100, a cardiopulmonary bypass system will be showcased at Arab Health 2025, one of the largest healthcare exhibitions in the Middle East, expected to have over 3,800 exhibitors and over 180 visiting countries.

RA'ANANA, Israel, Dec. 27, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), (NASDAQ: IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory support technology company, a pioneer in life-support technology, today announced the pricing of a private placement offering consisting of the issuance and sale of 4,608,715 ordinary shares, no par value per share (or pre-funded warrants in lieu thereof) and ordinary warrants to purchase up to 4,608,715 ordinary shares, at a combined purchase price of $0.70. The ordinary warrants have a term of eighteen months and have an exercise price of $1.10 per share.

RA'ANANA, Israel, Dec. 16, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory support technology company, announced the delivery of INSPIRA™ ART100 systems to its U.S. distributor, Glo-Med Networks Inc ("Glo-Med"). The systems were shipped in fulfilment of a purchase order issued by Glo-Med to Inspira.

The delivered INSPIRA™ ART100 systems will be distributed to sales targets across hospitals on the U.S. east coast and distributed to a cardiothoracic surgery division at a leading New York hospital, ranked among the top 15 percent of cardiothoracic programs in the U.S., with a view to collaborating with such hospital. The Company believes that the delivery of the INSPIRA™ ART100 to the U.S. market serves the Company's goal well to introduce physicians and perfusionists to Inspira's technologies and brand via initial deployments at leading hospitals.

RA'ANANA, Israel, Dec. 10, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies" or the "Company"), a groundbreaking life support technology company, revealed the expansion of its HYLA blood sensor technology ("HYLA") into an immediate personalized Blood Lab Test, aimed at performing real-time patient blood work for the rapid detection in minutes of the potential development of an underlying life-threatening medical condition.

The HYLA business model is designed to replace the need for nurses to take intermittent physical blood samples from patients undergoing extracorporeal procedures by providing patient blood work with pre-determined setup options, or alternatively, supporting physical immediate intermittent blood work testing and analysis. The HYLA is expected to be used near a patient's bed in ER's, ICU's, Medical Units and in operating rooms, with the potential to replace expensive equipment, eliminate the need for blood cartridges and dependency on central labs and reduce the burden on hospital staff. The HYLA technology could also potentially reduce countless tests performed each year where valuable time is often lost between the time of ordering a blood test and when test results are received, which can impact patient treatment and outcomes.

RA'ANANA, Israel, Dec. 4, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN), (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, entered into a strategic collaboration with Westchester Medical Center in Valhalla, New York. Westchester Medical Center, the flagship hospital in the Westchester Medical Center Health Network, will evaluate the performance and effectiveness of the new U.S. Food and Drug Administration (FDA) cleared INSPIRA ART100 systems in various real-world clinical scenarios, exposing Inspira's products and technologies to leading physicians and medical institutions.

RA'ANANA, Israel, Nov. 8, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), ("Inspira Technologies" or the "Company"), an innovative medical technology company in the life support and respiratory treatment arena, is pleased to invite investors to a webinar on November 11, 2024, at 4:15 p.m. EST.

The exclusive event, hosted by RedChip Companies, will feature Joe Hayon, President of Inspira Technologies, who will highlight the Company's developments, including its development of innovative life support technology, designed to monitor and elevate declining blood oxygen saturation levels in minutes without mechanical ventilation, that could disrupt the $19 billion mechanical ventilation market. A live Q&A session will follow the presentation.

The Company has signed a distribution agreement that assigns to Glo-Med the role of Inspira's primary distributor and customer support center in the U.S.

RA'ANANA, Israel, Oct. 24, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, is pleased to announce that it has entered into an agreement with Glo-Med Networks Inc ("Glo-Med"), which will serve as Inspira's primary distributor in the United States. Glo-Med's distribution facility will serve as a support center for the deployment of the INSPIRA ART100 in the United States. The INSPIRA ART100 is U.S. Food and Drug Administration (FDA) 510(k)-cleared for Cardiopulmonary Bypass (CPB) procedures.

RA'ANANA, Israel, Oct. 9, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking respiratory support technology company, is pleased to announce the development of a new disposable kit for the perfusion market. This strategic move is central to Inspira's business strategy of generating recurring revenues for products to be deployed in conjunction with the INSPIRA ART100 and that are also intended to be compatible with other life support machines, thus potentially tapping into the $1 billion perfusion systems market.